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Abstract To delineate the role of the cytoplasmic tail in the
distinct binding and coupling properties of human dopamine D1-
like receptors, chimeric receptors were generated in which the
entire tail region of wild-type human D1A (or D1) and D1B (or
D5) receptors was exchanged. The hD1A-D1BT, but not hD1B-
D1AT, receptor expression was dramatically reduced compared
with wild-type receptor expression. Swapping the cytoplasmic
tail resulted in a full switch of dopamine binding affinity and
constitutive activity, while dopamine potency decreased and
agonist-mediated maximal activation of adenylyl cyclase in-
creased for both chimeras. Hence, the cytoplasmic tail plays a
crucial role in D1-like receptor expression, agonist binding
affinity and constitutive activation but regulates in a distinct
fashion the formation of D1A and D1B receptor active states
upon dopamine binding.
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1. Introduction
The broad physiological e¡ects of dopamine are mediated
by D1-like and D2-like receptors that belong to the super-
family of G protein-coupled receptors (GPCRs) [1]. In mam-
mals, dopaminergic D1-like receptors are divided into two
subtypes, D1A (or D1) and D1B (or D5) which couple to
the activation of adenylyl cyclase [1]. The binding and cou-
pling properties of the D1B receptor di¡er from that of the
D1A receptor by a higher constitutive activity (agonist-inde-
pendent activity), an increased a⁄nity and potency for ago-
nists, as well as a lower a⁄nity for inverse agonists [2]. The
functional characteristics of D1B receptors resemble those of
constitutively active mutant GPCRs [3]. However, the struc-
tural determinants and molecular interactions underlying
these di¡erences in ligand binding and activation properties
of D1A and D1B receptors are poorly understood.
Mutagenesis studies suggest that GPCRs exist in an equi-
librium between two interchangeable conformational states,
inactive (R) and active (R*) [3^6]. In the absence of ligand
(agonist), GPCRs are predominantly maintained in an inac-
tive R state by intramolecular constraints that prohibit inter-
actions with G proteins. These intramolecular constraints are
released upon agonist binding or by mutations. Constitutively
active mutant GPCRs have a greater propensity to adopt an
R* state in the absence of agonist [4,5]. For instance, muta-
tions in the carboxyl end of the third cytoplasmic loop of
GPCRs can result in mutant receptors displaying high levels
of agonist-independent activity or constitutive activation [3,6].
Importantly, naturally occurring activating mutations of
GPCRs have been shown to underlie numerous pathological
conditions [6,7].
Previously, we have shown that a variant amino acid found
in a similar region of the carboxyl end of the third cytoplas-
mic loop of human D1A and D1B receptor could partially
explain the distinguishing features of these two receptors [8].
In a recent study, we have shown that the terminal receptor
locus (TRL), a domain encompassing transmembrane regions
6 and 7 as well as the third extracellular loop (EL3) and
cytoplasmic tail, is an important structural domain regulating
dopamine binding, constitutive activation and coupling prop-
erties of D1-like receptors [9]. Speci¢cally, swapping the TRL
between D1A and D1B receptors resulted in a switch in the
a⁄nity of these chimeric receptors for dopamine, as well as
agonist-independent activity and dopamine potency, when
compared with wild-type receptors. However, the di¡erence
observed in agonist-mediated maximal activation of adenylyl
cyclase elicited by D1A and D1B receptors was not altered in
cells expressing these chimeric receptors. The construction of
two additional chimeras, where just the EL3 region was ex-
changed between D1A and D1B receptors, mapped this region
as the domain underlying the degree of agonist-mediated max-
imal activation elicited by the D1-like receptors [9]. Hence, it
appears that discrete receptor domains are responsible for
regulating speci¢c GPCR activation properties (e.g. constitu-
tive activation and agonist-mediated maximal activation of
adenylyl cyclase) and these properties can be separated with
speci¢c mutations.
Our recent study [9] raises the issue of the potential role the
cytoplasmic tail plays in the TRL regulation of functional
properties of the D1A and D1B receptors. The human D1A
and D1B receptors share only about 30% identity between the
cytoplasmic tails. In addition, the human D1B cytoplasmic
tail contains more acidic amino acids than the D1A cytoplas-
mic tail (V20% vs. V10%). These features suggest the pres-
ence of sequence-speci¢c motifs within the cytoplasmic tail
that regulate the binding and coupling properties of D1A
and D1B receptors. Studies using gold¢sh D1A (a naturally
truncated form of the receptor) and chimeric Xenopus D1A
and D1B receptors suggested that the cytoplasmic tail does
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not play a major role in the dopamine binding and coupling
properties of these vertebrate D1-like receptors [10,11]. How-
ever, there is a signi¢cant degree of divergence within the
cytoplasmic tail between the human and Xenopus D1-like re-
ceptors (58^72%). Hence, the sequence-speci¢c motifs within
the human cytoplasmic tail may be responsible for some of
the functionally divergent roles of D1-like receptor subtypes.
In the study described herein, the cytoplasmic tail was ex-
changed between the human D1A and D1B receptor to exam-
ine the potential role of this region in the unique binding and
coupling properties of D1-like receptors. To our knowledge,
our study provides the ¢rst evidence for an important role of
the cytoplasmic tail in the regulation of the ligand binding and
activation properties of the D1A and D1B receptors.
2. Materials and methods
2.1. Drugs
N-[Methyl-3H]SCH23390 (83 Ci/mmol), [3H]adenine (26 Ci/mmol)
and [14C]cAMP (275 mCi/mmol) were from Amersham Pharmacia
Biotech. Dopamine, deschloro-SCH23390 (SCH23982), £upentixol
and (+)-butaclamol were purchased from Research Biochemicals In-
ternational. 1-Methyl-3-isobutylxanthine (IBMX) was obtained from
Sigma.
2.2. Construction of chimeric human D1A and D1B receptors
The cytoplasmic tail region of the human D1A and D1B receptor
was swapped by gene splicing using a PCR-based overlap extension
approach. The receptor sequences were swapped at the junction be-
tween the seventh transmembrane domain and the cytoplasmic tail.
This region corresponds to amino acid residue 334 in D1A and res-
idue 362 in D1B. To facilitate the construction of these chimeric
receptors, a silent mutation was introduced in each construct to create
a unique restriction endonuclease site. Speci¢cally, a MluI site was
introduced at amino acid residues 331 and 332 (5P-TATGCC-
3PC5P-TACGCG-3P) near the 3P end of transmembrane seven of
the D1A receptor, immediately upstream of the D1B receptor tail
sequence. Likewise, a HindIII site was introduced at residues 367
and 368 (5P-AAGGCA-3PC5P-AAAGCT-3P), which is located 3P of
the junction between the seventh transmembrane domain of the D1B
receptor and D1A receptor tail sequence. The resulting chimeras,
referred to as hD1A-D1BT and hD1B-D1AT, were subcloned in
pBluescript II SK (Stratagene) and their identity was con¢rmed by
dideoxy sequencing using Sequenase version 2.0 kit (US Biochemical
Corp.). Sequencing of the D1B-D1A tail receptor revealed the intro-
duction of a silent point mutation encoding amino acid residue 357
(5P-GTC-3PC5P-GTT-3P). Expression constructs for the wild-type and
chimeric receptors were engineered into the expression vector pCMV5.
2.3. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells (American Type
Culture Collection, Manassas, VA, USA) were cultured at 37‡C and
5% CO2 in minimal essential medium (MEM) supplemented with 10%
heat-inactivated fetal bovine serum and gentamicin (100 Wg/ml) (Life
Technologies, Inc.). Cells were seeded into 100-mm dishes (2.5U106
cells/dish) and transiently transfected with 0.05^5 Wg of DNA/dish
using a modi¢ed calcium phosphate precipitation procedure as de-
scribed [12].
2.4. Membrane preparation
Following an overnight incubation with the DNA^calcium phos-
phate precipitate, HEK293 cells were washed with phosphate-bu¡ered
saline (PBS), trypsinized, reseeded in 150-mm dishes and grown for an
additional 48 h. Transfected HEK293 cells were then washed with
cold PBS, scraped from the dish in ice-cold lysis bu¡er (10 mM
Tris^HCl, pH 7.4, 5 mM EDTA) and centrifuged twice at 40 000Ug
for 20 min at 4‡C. The crude membrane pellet was resuspended in
lysis bu¡er using a Brinkmann Polytron (17 000 rpm for 15 s), frozen
in liquid nitrogen and stored at 380‡C until used.
2.5. Radioligand binding assay
Frozen membranes were thawed on ice and resuspended in binding
bu¡er (50 mM Tris^HCl, pH 7.4, 120 mM NaCl, 5 mM KCl, 4 mM
MgCl2, 1.5 mM CaCl2, 1 mM EDTA) using a Brinkmann Polytron.
Binding assays were performed with 100 Wl of membrane in a total
volume of 500 Wl using N-[methyl-3H]SCH23390 as radioligand. Sat-
uration studies were done on fresh membrane using concentrations of
N-[methyl-3H]SCH23390 ranging from 0.01 to 6 nM. Non-speci¢c
binding was determined by the addition of 10 WM £upentixol. For
competition studies, membranes were incubated in a constant concen-
tration of N-[methyl-3H]SCH23390 (V0.6 nM) and increasing con-
centrations of competing ligand. Competition studies using dopamine
were done in the presence of 0.1 mM ascorbic acid. Binding assays
were incubated for 90^120 min at room temperature and terminated
with rapid ¢ltration through glass ¢ber ¢lters (GF/C, Whatman). The
¢lters were washed four times with 5 ml of cold washing bu¡er
(50 mM Tris^HCl, pH 7.4, 120 mM NaCl) and bound radioactivity
was determined by liquid scintillation counting (Beckman Counter,
LS1701). Protein concentration was measured using the Bio-Rad as-
say kit with bovine serum albumin as standard. To determine the
equilibrium dissociation constant (Kd) and binding capacity (R) val-
ues, binding isotherms were analyzed using the non-linear curve-¢tting
program LIGAND [13].
2.6. Whole cell cAMP assay
Regulation of adenylyl cyclase activity by wild-type and chimeric
receptors was assessed using a whole cell cAMP assay as described
previously [9]. Following overnight incubation with the DNA^calcium
phosphate precipitate, HEK293 cells were reseeded in 6- or 12-well
dishes. The next day, the growth medium was replaced with fresh
MEM containing 5% (v/v) fetal bovine serum, gentamicin (100 Wg/
ml) and [3H]adenine (2 WCi/ml) for 16^18 h at 37‡C and 5% CO2. The
labeling medium was then removed and HEK293 cells were incubated
in 20 mM HEPES-bu¡ered MEM containing 1 mM IBMX in the
presence or absence of dopamine for 30 min at 37‡C. At the end of
the incubation period the medium was aspirated and each well was
¢lled with 1 ml of lysis solution containing 2.5% (v/v) perchloric acid,
1 mM cAMP and [14C]cAMP (2.5^5 nCi, V5000^10 000 cpm) for
30 min at 4‡C. The lysates were then transferred to tubes containing
0.1 ml of 4.2 M KOH (neutralizing solution) and precipitates were
sedimented by a low speed centrifugation (1500 rpm) at 4‡C. The
amount of intracellular [3H]cAMP was determined from super-
natants puri¢ed by sequential chromatography using DOWEX and
alumina columns as previously described [14]. The amount of
[3H]cAMP (CA) over the total amount of intracellular [3H]adenine
(TU) was calculated to determine the relative adenylyl cyclase activity
(CA/TU). Dose^response curves to dopamine were analyzed by a
four-parameter logistic equation using ALLFIT [15]. Receptor ex-
pression was determined using a saturating concentration (V6 nM)
of N-[methyl-3H]SCH23390.
2.7. Statistics
Equilibrium dissociation binding constants (Kd) are expressed using
the geometric mean þ S.E.M. as described [16]. All other data are
reported as arithmetic means þ S.E.M. unless stated otherwise. All
statistical tests used in this study have been described elsewhere
[17,18]. Homoscedasticity of variances were assessed using Cochran
or Bartlett tests prior to statistical analyses. One-sample t-test and
analysis of variance (one-way ANOVA) with Newman^Keuls
multiple comparison test were performed using GraphPad Prism ver-
sion 3.00 for Windows, GraphPad Software, San Diego, CA, USA,
www.graphpad.com. The level of signi¢cance was established at
P6 0.05.
3. Results
3.1. Chimeric receptors delineate a structural domain
underlying receptor expression and dopamine a⁄nity for
human D1 receptor subtypes
The binding a⁄nities (Kd values) of the radioligand N-
[methyl-3H]SCH23390 for wild-type and chimeric human D1
receptors obtained using saturation studies are shown in Table
1. The similar Kd values indicate that the chimeric receptors
retained their ability to bind N-[methyl-3H]SCH23390 with
high a⁄nity. Compared with hD1A, hD1B and hD1B-
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D1AT receptors, hD1A-D1BT receptors displayed a signi¢-
cant increase in binding a⁄nity for N-[methyl-3H]SCH23390
(Table 1). In addition, there was a signi¢cant reduction (V15-
fold) in the expression of the hD1A-D1BT receptor, compared
with both parent wild-type receptors and the hD1B-D1AT
receptor (Table 1). Increasing the amount of transfected
DNA to 10 Wg did not augment signi¢cantly the hD1A-
D1BT receptor expression (data not shown).
Competition studies were performed to determine whether
the cytoplasmic tail contains the underlying structural require-
ments to in£uence dopamine binding to wild-type human
D1A and D1B receptors. As previously reported [2,8,9], dop-
amine exhibited a higher a⁄nity (V11-fold) for the D1B sub-
type in comparison with the D1A receptor (Table 1). Impor-
tantly, the hD1A-D1BT receptor displayed an increased
a⁄nity for dopamine that was indistinguishable from the
binding a⁄nity observed for the wild-type D1B receptor (Ta-
ble 1). Reciprocally, the hD1B-D1AT receptor bound dopa-
mine with a lower a⁄nity that was similar to that observed
for the wild-type D1A receptor (Table 1).
3.2. The cytoplasmic tail does not govern the binding a⁄nity of
antipsychotics
Previous studies have shown that antagonists bind to the
D1B receptor with lower a⁄nity in comparison with the D1A
receptor [2,8,9]. We tested the binding a⁄nity of £upentixol
and (+)-butaclamol, two antipsychotic drugs that display in-
verse agonism at both D1 receptor subtypes [2,19]. Both drugs
have lower a⁄nity for the wild-type D1B versus the D1A
receptor (Table 1). The binding a⁄nity of both chimeras for
£upentixol was not statistically di¡erent from their respective
parent receptors (Table 1). A similar trend applies for (+)-
butaclamol, except that the hD1A-D1BT receptor displayed
an increased a⁄nity for this drug compared with wild-type
D1A receptor (Table 1).
Next, we studied the binding properties of the benzazepine
SCH23982, a high a⁄nity antagonist that binds selectively to
D1-like receptors [20] but behaves as a partial agonist toward
D1 receptors when expressed in HEK293 cells [2]. In the
present study, SCH23982 exhibited a lower a⁄nity for the
wild-type D1B subtype compared to the D1A receptor. Sur-
prisingly, both chimeras bound SCH23982 with an increased
a⁄nity in comparison with their parent receptor (Table 1). A
similar ¢nding was observed with the swapping of the TRL
cassette [9].
3.3. Swapping the tail caused a full switch in agonist-
independent activity
The role of the cytoplasmic tail in agonist-independent ac-
tivation of adenylyl cyclase by wild-type and chimeric recep-
tors was assessed using a whole cell cAMP assay. In initial
experiments (Fig. 1A), HEK293 cells were transfected with
5 Wg of DNA for each of the four receptors. As previously
reported [2,8,9], the D1B receptor displayed a signi¢cant in-
crease in agonist-independent activity compared to the D1A
receptor (Fig. 1A,B). The D1A tail of the hD1B-D1AT recep-
tor dramatically reduced the constitutive activity of the D1B
receptor to a signi¢cantly lower level than was measured for
the wild-type D1A receptor (Fig. 1A,B). To our surprise,
however, this e¡ect was not reciprocal. In fact, the agonist-
independent activity of the hD1A-D1BT receptor exhibited a
signi¢cant reduction compared with the D1A receptor (Fig.
1A,B). Importantly, the average receptor expression of D1A,
D1B, D1A-D1BT and D1B-D1AT receptor in these experi-
ments was 13.9 þ 4.07, 14.4 þ 4.37, 1.17 þ 0.35 and 13.8 þ 3.11
pmol/mg protein, respectively. This issue is of importance
since a linear relationship exists between receptor density
and constitutive activity [2,5,21,22].
To determine whether this unexpected decrease in constitu-
tive activity of the hD1A-D1BT receptor was a function of its
signi¢cantly reduced expression (see above; Table 1), we
measured the constitutive activity of each receptor following
transfection with increasing amounts of DNA to obtain di¡er-
ent levels of receptor expression (Fig. 1C). Comparison of the
slopes obtained from the linear regression of the curves re-
vealed that swapping the tail between D1A and D1B receptors
does in fact cause a reciprocal switch in the slope and hence
level of constitutive activity. The reciprocity of this switch is
evident when the slope factor from each linear regression in
Fig. 1C is expressed relative to the D1A receptor (Fig. 1D).
Expression of the D1B tail in the context of the D1A receptor
caused an increase (V5-fold) in agonist-independent activity
to levels comparable with the D1B receptor. In contrast, the
hD1B-D1AT receptor displayed a dramatic reduction in con-
stitutive activity to levels indistinguishable from the D1A re-
ceptor (Fig. 1D).
3.4. Coupling properties of D1A and D1B receptor chimeras
Di¡erences in agonist-mediated coupling properties of D1A
and D1B receptors have been reported previously [2,8,9]. To
test whether the cytoplasmic tail delineates the structural re-
quirements for dopamine potency (EC50) and agonist-medi-
ated maximal activation, dose^response curves were done in
HEK293 cells expressing similar levels of wild-type and chi-
Table 1
Dissociation constants (Kd) and binding capacity (R) values for
wild-type and chimeric receptors
Kd and R values are expressed as geometric and arithmetic means
þ S.E.M., respectively. Means are from four to ¢ve experiments
done in duplicate determinations. [3H]-SCH, N-[methyl-3H]-
SCH23390; DA, dopamine; FLU, £upentixol; BUTA, (+)-butacla-
mol; SCH, SCH23982.
*P6 0.05 when compared with hD1A; iP6 0.05 when compared
with hD1B; #P6 0.05 when compared with hD1B-D1A tail recep-
tor.
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meric receptors. As shown in Fig. 2A, dopamine potency was
V10-fold greater at wild-type D1B receptor compared with
wild-type D1A receptor. In comparison with their parent re-
ceptors, hD1A-D1BT and hD1B-D1AT chimeras displayed a
signi¢cant 5- and 15-fold decrease, respectively, in dopamine
potency (Fig. 2A).
As previously described [2,9], agonist-mediated maximal
stimulation elicited by the wild-type D1A receptor is signi¢-
cantly greater than the wild-type D1B receptor (Fig. 2B). In-
terestingly, there was a signi¢cant increase in the maximal
activation of adenylyl cyclase following agonist stimulation
of both D1A-D1BT and D1B-D1AT receptors, compared
with their parent receptors (Fig. 2B).
4. Discussion
In the present study, we show for the ¢rst time that the
cytoplasmic tail is a crucial structural determinant regulating
the distinct binding and activation properties of the human
D1A and D1B receptors. Several studies have implicated the
cytoplasmic tail of GCPRs in G protein coupling and second
messenger activation, partial agonist activity, constitutive ac-
tivation, and receptor desensitization and/or internalization
[10,23^29]. Recently, GABAA-ligand-gated channels have
been shown to complex selectively with D1B receptors
through the direct binding of the D1B cytoplasmic tail with
the second intracellular loop of the GABAA Q2(short) receptor
subunit, resulting in a co-directional decrease in GABAA and
D1B receptor function [30]. Importantly, our present study
may provide insights into the molecular basis for the physical
interaction between D1B and GABAA receptors.
By constructing chimeric receptors, we have clearly shown
that the cytoplasmic tail of human dopamine D1-like recep-
tors, which is unlikely to play a direct role in the docking of
extracellular agonists and antagonists, regulates the binding
a⁄nity of the natural ligand, dopamine. In contrast, exchang-
ing the tail region had little e¡ect on the binding a⁄nity of
inverse agonists for the chimeric receptors, compared with
wild-type receptors. This suggests that inverse agonist binding
is most likely independent of tail-induced conformational
changes. Alternatively, this binding may be modulated by
residues conserved in the cytoplasmic tail of both D1-like
receptors and rely also upon interactions with di¡erent resi-
dues outside of the tail region.
In addition, our results permit us to narrow down the struc-
tural region(s) responsible for dopamine binding a⁄nity and
constitutive activity, which we previously attributed to the
TRL cassette, a large domain encompassing transmembrane
Fig. 1. Constitutive activity of wild-type and chimeric D1 receptors expressed in HEK293 cells. Basal levels of intracellular cAMP were deter-
mined in single wells of a six-well dish using whole cell cAMP assays (A) and calculated relative to hD1A receptor (B). Data are expressed as
geometric mean þ S.E.M. of three experiments done in triplicate determinations. C: A representative example (n = 2) of basal intracellular levels
of cAMP versus receptor expression (pmol/mg protein) following transfection of HEK293 cells with wild-type and chimeric receptors using four
di¡erent amounts of DNA (0.005, 0.05, 0.5 and 5 Wg). D: The slope factor for each line plotted in C is expressed relative to hD1A receptor.
*P6 0.05 when compared to hD1A; #P6 0.05 when compared with hD1A-D1BT; iP6 0.05 when compared with hD1B-D1AT. CA/TU,
[3H]cAMP formed divided by the total uptake.
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regions 6 and 7 as well as EL3 and the cytoplasmic tail [9].
While it was determined that the EL3 region was responsible
for partial modulation of dopamine binding a⁄nity and ago-
nist-independent activity [9], we have shown that swapping
the cytoplasmic tail region caused a full switch in both proper-
ties. Hence, there is some overlap or complementation in the
contribution of these distinct structural domains to the con-
formation of D1-like receptors. Interestingly, the major deter-
minants of K2- and L2-adrenergic receptor agonist and antag-
onist ligand binding speci¢city are contained within the
seventh membrane-spanning domain and several of the ¢rst
¢ve hydrophobic domains may contribute to agonist binding
speci¢city [31]. Perhaps the cytoplasmic tail of D1A and D1B
receptors di¡erentially modulates the three-dimensional ar-
rangement of the transmembrane domains that provide the
binding pocket for dopamine [32,33], resulting in distinct ag-
onist binding a⁄nities for these receptor subtypes. Similarly,
amino acid sequences of the intracellular loops mediate the
interaction of GPCRs with G protein [33,34]. Our ¢ndings
suggest that the cytoplasmic tail interacts directly or indirectly
with this region to modulate G protein coupling and second
messenger activation, as measured by changes in agonist-in-
dependent adenylyl cyclase activity. Hence, in the process of
making our chimeric receptors, the direct or indirect ‘native’
interactions of amino acids in the tail with those in the intra-
cellular loops and/or transmembrane domains are switched
and now re£ect those of the cognate wild-type receptor coun-
terpart.
The tail region of human D1-like receptors, in particular
the D1B tail, also appears to play an important role in deter-
mining the level of functional receptor expression in the plas-
ma membrane of human (HEK293) cells. This was evident by
a 15-fold decrease in the binding capacity of hD1A-D1BT
receptor compared with hD1A, hD1B and hD1B-D1AT re-
ceptors. Perhaps the D1B tail, expressed in the context of a
D1A receptor, prevents the chimera from being e⁄ciently
routed to the plasma membrane or may reduce the stability
of the receptor in the membrane causing it to be quickly
recycled from the surface. For example, the D1B tail in a
D1A receptor ‘environment’ may not bind as e⁄ciently to
cytoskeletal elements or other membrane proteins that anchor
the receptor in the plasma membrane, therefore increasing
lateral movement to coated pits. This lateral movement is
presumably a prerequisite for ligand-induced endocytosis
and subsequent down-regulation [35,36]. Our ¢nding that
the D1B tail causes the D1A receptor to ‘behave’ more like
a D1B receptor, as measured by an increase in constitutive
activity, suggests that this chimeric receptor is e⁄ciently
routed to the plasma membrane and coupled to Gs protein,
but is quickly recycled. In fact, studies have shown that acti-
vating mutations may lead to mutant GPCRs that are struc-
turally unstable [37,38]. In addition, Parker and Ross [39]
have shown that truncation of the cytoplasmic tail of the
turkey L-adrenergic receptor increases its susceptibility to ami-
no-terminal proteolysis.
The present study describes an important function of the
cytoplasmic tail in regulating the intramolecular interactions
underlying some of the distinct binding and coupling proper-
ties of the D1 receptor subtypes. The majority of our ligand
binding and G protein coupling data suggest that the intra-
molecular interactions induced by the D1A tail in the hD1B-
D1AT chimera maintain this receptor in a predominantly
‘constrained’ conformation, as indexed by a decreased binding
a⁄nity and potency for dopamine, and a lower agonist-inde-
pendent activity. While these ¢ndings might lead one to con-
clude that the e⁄cacy of coupling to Gs of hD1B-D1AT re-
ceptor is reduced and now resembles the D1A receptor, the
observed increase in maximal activation of adenylyl cyclase is
not consistent with such a general conclusion. Similarly, initial
¢ndings that the D1B tail enabled the D1A-D1BT receptor to
increase its binding a⁄nity for dopamine and constitutive
activity suggested that this region induces intramolecular in-
teractions enabling the chimera to adopt a more ‘relaxed’
conformation. However, the observed decrease in dopamine
potency of the D1A-D1BT receptor compared with wild-type
Fig. 2. Dopamine-mediated stimulation of adenylyl cyclase activity
by wild-type and chimeric D1 receptors expressed in HEK293 cells.
A: Dose^response curve of dopamine for adenylyl cyclase stimula-
tion by wild-type and chimeric D1 receptors. Each point is the
arithmetic mean þ S.E.M. of four to ¢ve experiments done in tripli-
cate determinations using single wells from a 12-well dish. For the
determination of EC50 values and maximal stimulation, each point
was ¢rst expressed as percentage of maximal response obtained with
the respective wild-type or chimeric receptor and curves were then
analyzed by simultaneous curve-¢tting using ALLFIT. The EC50
values are as follows (in nM): 7.0 þ 0.6 (hD1A), 1.0 þ 0.2 (hD1B),
33.3 þ 0.2 (hD1A-D1BT), and 15.0 þ 0.2 (hD1B-D1AT). The recep-
tor expression in pmol/mg of membrane protein (expressed as the
arithmetic mean þ S.E.M.) was 3.69 þ 0.24 (hD1A), 2.55 þ 0.51
(hD1B), 0.77 þ 0.08 (hD1A-D1BT), and 2.61 þ 0.69 (hD1B-D1AT).
B: Maximal activation of adenylyl cyclase in HEK293 cells trans-
fected with wild-type and chimeric D1 receptors. The maximal acti-
vation values were determined using ALLFIT as described in A.
Statistical signi¢cance was determined following unconstrained and
constrained curve ¢tting. *P6 0.05 when compared to hD1A;
#P6 0.05 when compared with hD1A-D1BT; iP6 0.05 when com-
pared with hD1B-D1AT.
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D1A receptor illustrates that even a full switch in dopamine
binding a⁄nity does not necessarily allow one to predict that
there will be similar changes in all coupling properties, i.e.
these phenomena can be separated. In fact, this statement is
further supported by our ¢nding of an increase, instead of a
decrease, in agonist-mediated maximal activation of adenylyl
cyclase in cells expressing hD1A-D1BT receptors. Overall,
these ¢ndings suggest that the D1A and D1B receptor can
undergo multiple active receptor conformations. Studies in
our laboratory are under way to de¢ne further the speci¢c
residues of the cytoplasmic tail responsible for these activation
properties.
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